Trans-Aqueduct Access to the Third Ventricle for Delivery of Medical Devices: A Feasibility Study

This feasibility study demonstrates that the trans-aqueduct approach is a technically viable, minimally invasive pathway for accessing the third ventricle to deliver therapeutic neurotechnologies to deep-brain targets, though further pre-clinical research is needed to evaluate its long-term safety and physiological tolerance.

The Gist

Imagine your brain is a bustling city, and deep inside that city, there are critical power plants (like the Subthalamic Nucleus and Globus Pallidus) that control movement and mood. When these power plants malfunction, people can suffer from conditions like Parkinson's disease or severe depression.

Traditionally, to fix these deep-seated issues, doctors have to perform "open-heart surgery" for the brain. They drill a hole in the skull and thread a wire directly into the tissue. It's effective, but it's invasive, risky, and requires a long recovery.

This paper explores a new, much gentler way to reach these deep brain targets. Think of it as finding a secret underground tunnel system that leads right to the city center, so you don't have to break through the city walls.

The Secret Tunnel: The "Trans-Aqueduct" Route

The researchers discovered a way to access the Third Ventricle, a small, fluid-filled room right in the center of the brain. This room is a "high-value real estate" location because it sits right next to the deep brain targets we need to reach.

Here is how their new method works, using a simple analogy:

1. The Entry Point (The Back Door)
Instead of drilling into the top of the skull, the team enters through the back of the neck, right into the spinal fluid space. Imagine sliding a very thin, flexible garden hose into a water pipe that runs all the way up your spine.

2. The Journey Up (The River)
They guide this hose up through the spinal cord, into the base of the brain, and into the Fourth Ventricle (a small chamber). From there, they need to squeeze through a very narrow, winding tunnel called the Cerebral Aqueduct.

• The Challenge: This tunnel is tiny—only about 1.6 millimeters wide (roughly the thickness of a standard pencil lead).
• The Solution: They used super-flexible, angled wires (like a snake-like guide) to navigate this tight squeeze without hitting the walls.

3. The Destination (The Central Hub)
Once they pass through the narrow tunnel, they pop out into the Third Ventricle. This is a larger, open room in the middle of the brain. From this central hub, the deep brain targets are just a short distance away (about the width of a thumb).

What Did They Find?

The team tested this idea on two things:

1. Computer Scans (MRI): They looked at 16 human brain scans to map the "road signs" and measure the size of the tunnels.
2. Cadavers (Donated Bodies): They actually tried the procedure on 6 preserved human bodies to see if the tools could physically fit and move through the path.

The Results:

• It Works: They successfully navigated the tunnel and reached the central room in 5 out of 6 bodies (83% success rate).
• The Size: The tunnel is tight, but it can comfortably fit medical tools up to 2.0 mm wide. In one case, they even managed to push a slightly larger tool (2.8 mm) through.
• The Time: The procedure took about 15 to 30 minutes just to get the tools in place. This is much faster than traditional brain surgery, which can take hours.
• The Safety: Because they are floating in fluid and not drilling into brain tissue, the risk of cutting or bruising the brain is theoretically much lower.

Why Does This Matter?

Think of this as upgrading from a sledgehammer to a lockpick.

• Current Method (Sledgehammer): You have to break the skull, drill a hole, and jam a device in. It's traumatic for the brain and takes weeks to heal.
• New Method (Lockpick): You slide a tiny, flexible tool up the spine, through a natural fluid tunnel, and into the center of the brain. It's minimally invasive, potentially faster, and could be done with less anesthesia.

The "But..." (Limitations)

The researchers are careful to say this is just the first step (a "feasibility study").

• Cadavers vs. Real Life: They tested this on preserved bodies. Real brains are softer, move with blood flow, and are under pressure. The "tunnel" might be tighter or more fragile in a living person.
• The "Traffic Jam": Sometimes the tunnel is blocked by a natural bridge of tissue (called the Massa Intermedia) that connects the two sides of the brain. Doctors will need to check MRI scans first to make sure the path is clear.
• Future Steps: Before this can be used on patients, they need to test it on living animals to make sure it doesn't cause swelling, bleeding, or other problems over time.

The Bottom Line

This paper proves that it is physically possible to reach the deep center of the brain through a tiny, natural tunnel in the spine, without cutting open the skull. It opens the door for a new generation of "minimally invasive" brain therapies that could one day treat Parkinson's, epilepsy, and depression with far less risk and recovery time than we have today.

Technical Summary

1. Problem Statement

Current neuromodulation technologies (e.g., Deep Brain Stimulation, Brain-Computer Interfaces) targeting deep brain structures like the Subthalamic Nucleus (STN) and Globus Pallidus internus (GPi) typically require open-brain neurosurgery (craniotomy). This poses significant risks, including hemorrhage, infection, and tissue trauma. Conversely, non-invasive methods (e.g., transcranial ultrasound) lack the precision to target deep nuclei due to signal attenuation by the skull.

Endovascular approaches are limited by the small, tortuous nature of deep cerebral veins and the high risk of thrombosis or immune response to blood-contacting devices. There is a critical need for a minimally invasive access route that avoids craniotomy and deep vascular navigation while providing a direct pathway to the deep brain.

2. Methodology

The study utilized a three-phase approach combining human MRI data and cadaveric specimens to evaluate the feasibility of a retrograde trans-aqueduct approach (accessing the third ventricle via the spinal column, fourth ventricle, and cerebral aqueduct).

• Phase 1: Morphometric MRI Analysis
  • Data: 16 diagnostic FLAIR 3D MRI datasets (mean age 48.4 years).
  • Task: Two independent raters measured dimensions of the cerebral aqueduct, third ventricle, and related structures (e.g., Massa Intermedia) to establish anatomical baselines.
• Phase 2: Cadaveric Access Simulation
  • Specimens: 6 embalmed human head-and-neck specimens (mean age 88.2 years).
  • Protocol: Specimens were positioned prone. A 5-Fr introducer sheath was inserted into the subarachnoid space at the cervical level. Under fluoroscopic guidance, guidewires (0.035" exchanged for a flexible 0.018" angled-tip) and catheters (4–6 Fr, with one case using 8.5 Fr) were advanced cranially through the cisterna magna, fourth ventricle, and cerebral aqueduct into the third ventricle.
  • Metrics: Success rate, procedural time, and qualitative resistance levels (None to Impassable) were recorded.
• Phase 3: Anatomical Dissection
  • Specimens: 3 specimens from the Phase 2 group.
  • Task: Direct dissection to visualize the pathway, measure the third ventricle cavity, and determine the spatial distance from the third ventricular centroid to the STN and GPi.

3. Key Contributions

• Novel Access Route: Demonstrated the technical feasibility of a trans-aqueduct approach as a minimally invasive alternative to craniotomy for deep brain device delivery.
• Anatomical Mapping: Provided precise morphometric data on the cerebral aqueduct and third ventricle dimensions in both living (MRI) and cadaveric populations.
• Device Compatibility: Established that the cerebral aqueduct can accommodate catheters up to 2.8 mm (8.5 Fr) in diameter with minimal resistance, suggesting compatibility with future implantable neurotechnologies.
• Spatial Correlation: Mapped the proximity of the third ventricle to key therapeutic targets (STN and GPi), confirming they are within a reachable distance (5–20 mm) from the ventricular centroid.

4. Key Results

• Anatomical Dimensions:
  • Cerebral Aqueduct: Mean diameter of 1.6 mm (SD 0.14) and mean length of 19.4 mm.
  • Third Ventricle: Average dimensions were ~27.6 mm (ventral-dorsal), 19.9 mm (caudal-cranial), and 5.7 mm (lateral width).
  • Target Proximity: The STN was located ~11.4 mm from the third ventricle centroid; the GPi was ~20.3 mm away.
• Procedural Feasibility:
  • Success Rate: Successful access to the third ventricle was achieved in 83% (5/6) of cadaveric specimens.
  • Resistance: Most cases (60%) showed "Minor" resistance. Moderate resistance was encountered with catheters ≥1.7 mm. One specimen failed due to tissue degradation from fixation, not anatomical impossibility.
  • Device Size: Catheters up to 2.8 mm (8.5 Fr) were successfully advanced in one specimen, and 2.0 mm (6 Fr) in others.
  • Time: Procedural time for access (excluding lumbar puncture setup) was 15–30 minutes.
• Comparison (Cadaver vs. MRI):
  • Aqueduct diameter measurements were highly consistent between cadaver and MRI (1.6 mm in both).
  • Third ventricle dimensions showed slight variations (cadaver measurements were generally smaller in anterior-posterior length due to post-mortem tissue shrinkage and gravity effects), but the differences were within an 11% margin.

5. Significance and Future Implications

• Clinical Potential: This approach offers a pathway to implant neuromodulation devices (e.g., electrodes, sensors) in the third ventricle to treat Parkinson's, essential tremor, and psychiatric disorders with significantly reduced surgical trauma compared to open-brain surgery.
• Safety Profile: By utilizing the natural CSF-filled lumen, the risk of hemorrhage and direct brain tissue trauma is theoretically lower than transcranial or intravascular approaches.
• Limitations & Next Steps:
  • The study was conducted on embalmed cadavers, which may have altered tissue stiffness and dimensions.
  • Future work requires in vivo animal studies to assess physiological tolerance, CSF flow dynamics, long-term implant safety, and the development of specialized, atraumatic catheter systems optimized for this specific trajectory.

Conclusion: The study confirms that the trans-aqueduct route is a technically feasible, minimally invasive pathway for delivering medical devices to the deep brain, warranting further pre-clinical and clinical investigation.